SEARCH

SEARCH BY CITATION

References

  • 1
    Madruga JV, Berger D, McMurchie Met al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370: 4958.
  • 2
    Arastéh K, Yeni P, Pozniak Aet al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther 2009; 14: 859864.
  • 3
    Haubrich R, Berger D, Chiliade Pet al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21: F11F18.
  • 4
    Katlama C, Esposito R, Gatell JMet al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21: 395402.
  • 5
    Mills AM, Nelson M, Jayaweera Det al. Once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23: 16791688.
  • 6
    Ortiz R, Dejesus E, Khanlou Het al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 13891397.
  • 7
    PREZISTA® (darunavir). EPARs for authorised medicinal products for human use. Updated 22 January 2013. Available at www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000707/human_med_000988.jsp&mid=WC0b01ac058001d124 (accessed 27 February 2013).
  • 8
    PREZISTA® (darunavir). Full prescribing information. Tibotec Inc. Revised February 2013. Available at www.prezista.com/sites/default/files/pdf/us_package_insert.pdf (accessed 27 February 2013).
  • 9
    Cahn P, Fourie J, Grinsztejn Bet al. ODIN: 48-week analysis of once- versus twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 2011; 25: 929939.
  • 10
    De Meyer S, Dierynck I, Lathouwers Eet al. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2. 16th International HIV Drug Resistance Workshop. Sitges, Spain, June 2008 [Abstract 31].
  • 11
    Johnson VA, Brun-Vezinet F, Clotet Bet al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17: 138145.
  • 12
    Johnson VA, Brun-Vezinet F, Clotet Bet al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16: 138145.
  • 13
    King MS, Lawal AA, Fredrick LMet al. Impact of baseline resistance on virologic outcome with once-daily (QD) or twice-daily (BID) lopinavir/ritonavir (LPV/r) through 48 weeks of combination antiretroviral therapy in treatment-experienced, HIV-1-infected subjects. 12th European AIDS Conference. Cologne, Germany, November 2009 [Abstract PE10.1/1].
  • 14
    De La Rosa G, Pattery T, Picchio Get al. Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003–2009. 10th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2010 [Abstract P132].
  • 15
    Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated 12 February 2013; 1166.
  • 16
    Powderly WG, Saag MS, Chapman Set al. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13: 18731880.
  • 17
    Vray M, Meynard JL, Dalban Cet al. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther 2003; 8: 427434.
  • 18
    Berger DS, Northland R, Scribner Aet al. Effect of baseline factors on virological response to darunavir/r and lopinavir/r at Week 48 in TITAN. 11th European AIDS Conference. Madrid, Spain, October 2007 [Abstract P7.3/27].
  • 19
    Weintrob AC, Grandits GA, Agan BKet al. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr 2009; 52: 574580.
  • 20
    Dierynck I, De Meyer S, Lathouwers Eet al. Comparable in-vitro susceptibility and virologic outcome to darunavir in patients infected with subtype B and subtype non-B HIV isolates participating in the ARTEMIS Phase III trial. XVIIth International AIDS Conference. Mexico City, Mexico, August 2008 [Abstract TUPE0049].
  • 21
    De Meyer S, Hill A, Picchio Get al. Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial. J Acquir Immune Defic Syndr 2008; 49: 563564.
  • 22
    Molina J-M, Cohen C, Katlama Cet al. Safety and Efficacy of Darunavir (TMC114) with low-dose Ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007; 46: 2431.
  • 23
    Maroldo L, Lawal A, Rivero Ret al. Effect of the M184V/I mutation and other nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations on virologic response to a lopinavir/ritonavir-based regimen. XVIII International AIDS Conference. Vienna, Austria, July 2010 [Abstract TUPE0119].
  • 24
    Miller V, Stark T, Loeliger AEet al. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med 2002; 3: 135145.
  • 25
    Whitcomb JM, Parkin NT, Chappey Cet al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188: 9921000.
  • 26
    Paterson DL, Swindells S, Mohr Jet al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 2130.